Venlafaxine-induced prostatism: a case report
Open Access
- 21 March 2017
- journal article
- case report
- Published by ScopeMed in Psychiatry and Clinical Psychopharmacology
- Vol. 27 (2), 197-198
- https://doi.org/10.1080/24750573.2017.1296398
Abstract
Venlafaxine, which is often used for a number of psychiatric-related conditions such as the treatment of major depression, generalized anxiety disorder, social anxiety disorder and panic disorder, is generally a drug that is well tolerated and safe. The side effects of drugs can cause the treatment to prematurely terminate. Clinicians should prefer appropriate and low side-effects drugs to prevent this. This situation is also especially important for psychiatric patients. Prostatism, which impairs quality of life, is an important medical condition, with clinical and social implications. In the previous studies, prostatism was declared as a side effect of some antidepressant such as milnacipran, duloxetine and reboxetine. In our case, we discussed that venlafaxine-related prostatism developed in a male patient. As far as we know this is the first report of venlafaxine-induced prostatism.Keywords
This publication has 6 references indexed in Scilit:
- Benign prostatic hyperplasia and prostate cancer: an overview for primary care physiciansInternational Journal of Clinical Practice, 2010
- Cardiovascular Changes Associated With Venlafaxine in the Treatment of Late-Life DepressionAmerican Journal of Geriatric Psychiatry, 2006
- Comparison of the effects of serotonin selective, norepinephrine selective, and dual serotonin and norepinephrine reuptake inhibitors on lower urinary tract function in catsLife Sciences, 2002
- ReboxetineCNS Drugs, 1999
- VenlafaxineDrugs, 1995
- A method for estimating the probability of adverse drug reactionsClinical Pharmacology & Therapeutics, 1981